News Releases

2019

Feb.19.2019 Ono and Seikagaku Announce the Topline Results from a Phase III Confirmatory Study of ONO-5704/SI-613 in Patients with Knee Osteoarthritis in Japan (96.1KB)
Feb.15.2019 Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) Demonstrates Continued Survival Benefit at 30-Month Follow-up in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (51.8KB)
Feb.15.2019 Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer (48.2KB)
Feb.01.2019 Announcement on Financial Results for FY2018 3Q
Jan.31.2019 ONO Announces a Strategic Partnership Agreement with Repare Therapeutics for a Pol-theta Inhibitor Program (108KB)
Jan.22.2019 ONO Selected by CDP as a Climate Change A List Company in 2018 (76.3KB)
Jan.18.2019 Opdivo® (Nivolumab) Intravenous Infusion Approved for Expanded Use in Non-Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy in Taiwan (71.4KB)
Jan.15.2019 European Commission Approves Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) for First-Line Treatment of Patients with Intermediate- and Poor-Risk Advanced Renal Cell Carcinoma (47.8KB)
Jan.15.2019 Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in BRAF-Mutant Metastatic Colorectal Cancer (36.2KB)
Jan.10.2019 Karyopharm Announces Submission of Marketing Authorization Application to the European Medicines Agency for Selinexor for the Treatment of Patients with Penta-Refractory Multiple Myeloma (35.3KB)
Jan.09.2019 Opdivo® (Nivolumab) Demonstrates a Significant Extension in Overall Survival Versus Chemotherapy in Patients with Unresectable Advanced or Recurrent Esophageal Cancer in Phase III Clinical Study (42.4KB)
Jan.08.2019 ONO Receives Manufacturing and Marketing Approval in Japan for Demser® Capsule, a Tyrosine Hydroxylase Inhibitor, for Improvement of Status of Catecholamine Excess Secretion and its Accompanying Symptoms in Patients with Pheochromocytoma (64.7KB)
Jan.08.2019 ONO Receives a Manufacturing and Marketing Approval for BRAFTOVI® Capsule, a BRAF Inhibitor and MEKTOVI® Tablet, a MEK Inhibitor for Indication of Unresectable BRAF-Mutant Melanoma in Japan (58.3KB)
Jan.07.2019 ONO Listed in FTSE4Good Index Series and FTSE Blossom Japan Index for Socially Responsible Investment (121KB)